Kolexia
Peyrin-Biroulet Laurent Gastro-entérologie
Peyrin-Biroulet Laurent
Gastro-entérologie
Hôpital Brabois
Vandoeuvre-lès-Nancy, France
1.4 K Activités
1.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladies inflammatoires intestinales Maladie de Crohn Rectocolite hémorragique Colite Ulcère Nécrose Inflammation COVID-19 Sténose pathologique

Collaborateurs

Voir plus
Laharie David
Laharie David
Hôpital Haut-lévêque, Pessac, France
Roblin Xavier
Roblin Xavier
Hôpital Nord CHU Saint-Étienne - Loire, Saint-Priest-en-Jarez, France
Fumery Mathurin
Fumery Mathurin
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France
Nancey Stephane
Nancey Stephane
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Abbvie
225 collaboration(s)
Dernière en 2023
Janssen
143 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
97 collaboration(s)
Dernière en 2023
Edimark
61 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1): A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Essai Clinique (Lilly)   15 mars 2024
LUCENT 2: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Essai Clinique (Lilly)   14 mars 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflammatory bowel diseases   09 mars 2024
Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
Gastro hep advances   07 mars 2024
LUCENT-URGE: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Essai Clinique (Lilly)   07 mars 2024
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
United European gastroenterology journal   28 février 2024
Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?
Gastroenterology & hepatology   27 février 2024
QUASAR: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Janssen)   27 février 2024
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Essai Clinique (Takeda Pharmaceutical)   20 février 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.
BMJ open gastroenterology   08 février 2024